Optimized multi-epitope constructs and uses thereof

Details for Australian Patent Application No. 2003287019 (hide)

Owner GENimmune N.V. Pharmexa Inc.

Inventors Chesnut, Robert; Power, Scott D.; Livingston, Brian D.; Deyoung, Lawrence M.; Sette, Alessandro; Newman, Mark J.; Huang, Manley T.F.; Babe, Lilia Maria; Chen, Yiyou

Agent Callinan

Pub. Number AU-B-2003287019

PCT Number PCT/US2003/0313

PCT Pub. Number WO2004/031210

Priority 60/419,973 22.10.02 US; 60/415,463 03.10.02 US

Filing date 3 October 2003

Wipo publication date 23 April 2004

Acceptance publication date 22 July 2010

International Classifications

A01N 63/00 (2006.01) Biocides, pest repellants or attractants, or plant growth regulators containing micro-organisms, viruses, microbial fungi, animals, e.g. nematodes, or substances produced by, or obtained from micro-organisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates

A61K 31/7088 (2006.01) - Compounds having three or more nucleosides or nucleotides

A61K 39/29 (2006.01) Medicinal preparations containing antigens or antibodies - Hepatitis virus

A61P 31/20 (2006.01) Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

C07H 21/04 (2006.01) Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

C07K 7/06 (2006.01) Peptides having 5 to 20 amino acids in a fully defined sequence

C07K 7/08 (2006.01) Peptides having 5 to 20 amino acids in a fully defined sequence

C07K 14/02 (2006.01) Peptides having more than 20 amino acids

C12N 7/00 (2006.01) Viruses, e.g. bacteriophages

C12N 15/11 (2006.01) Mutation or genetic engineering - DNA or RNA fragments

C12N 15/33 (2006.01) Mutation or genetic engineering - Genes encoding viral proteins

C12N 15/36 (2006.01) Mutation or genetic engineering

C12N 15/63 (2006.01) Mutation or genetic engineering - Introduction of foreign genetic material using vectors

Event Publications

1 April 2004 Complete Application Filed

  Priority application(s): 60/419,973 22.10.02 US; 60/415,463 03.10.02 US

27 May 2004 Application Open to Public Inspection

  Published as AU-B-2003287019

26 June 2008 Assignment before Grant

  Epimmune Inc.; Genencor International, Inc. The application has been assigned to Pharmexa Inc.; GENimmune N.V. 2004

22 July 2010 Application Accepted

  Published as AU-B-2003287019

5 August 2010 Alteration of Name

  The name of the applicant has been altered to GENimmune N.V.; EPPIMMUNE INC 2004

16 September 2010 Alteration of Name

  The name of the applicant has been altered to GENimmune N.V.; EPIMMUNE INC. 2004

18 November 2010 Standard Patent Sealed

26 April 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003287020-POWER PLANT AND DRIVELINE FOR VEHICLES

2003287018-COMPOSITIONS AND METHODS FOR TREATING ARTHRITIC DISORDERS